ランタス(インスリングラルギン)バイオシミラー臨床試験&機会インサイト

◆英語タイトル:Lantus (Insulin Glargine) Biosimilar Clinical Trial & Opportunity Insight
◆商品コード:DATA611003
◆発行会社(リサーチ会社):PNS Pharma
◆発行日:2016年10月
◆ページ数:35
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single UserUSD1,000 ⇒換算¥113,000見積依頼/購入/質問フォーム
Multi UserUSD2,000 ⇒換算¥226,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はPNS Pharma社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。PNS Pharma社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

“Lantus (Insulin Glargine) Biosimilar Clinical Trial & Opportunity Insight” report by PNS Pharma gives comprehensive clinical insight on 37 biosimilar version of Lantus drug in clinical pipeline. Currently 5 biosimilar version of Lantus are commercially available in India, Japan, Kenya, Czech Republic, Estonia, Germany, China, Slovakia, United Kingdom for the treatment of Type 1 & 2 diabetes mellitus. The patent on Lantus expired in 2014. Lantus is the brand name for Insulin Glargine, a man made form of hormone generally produced in the human body, used in the treatment of diabetes mellitus in children and adults. The long lasting process of insulin works to lower down the levels of glucose (sugar) in blood. Lantus is also used to treat type 2 & type 1 diabetes in adults and children having more than 6 years of age. The drug usually starts working after several hours of injection and keeps performing for 18-26 hours or more without any pronounced peak.
Lantus is a package consisting of a sterile solution of insulin glargine containing zinc, m-cresol, glycerol 85%, polysorbate and water for injection as inactive ingredients. Each milliliter of Lantus contains 100 Units (3.6378mg) of insulin glargine. The pH of Lantus is adjusted by addition of hydrochloric acid and sodium hydroxide. It has a pH value of approximately 4 making it completely soluble. It is produced by recombinant DNA technology using a non-pathogenic laboratory strain of Escherichia coli (K12) acting as production organism. Chemical representation of insulin glargine present in Lantus is 21A-Gly-30Ba-L-Arg-3030b-L-Arg-human insulin and empirical formula as C267H404N72O78S6 and a molecular weight of 6063.
The key function of Lantus consisting insulin is to regulate blood sugar levels is performed by stimulating peripheral glucose uptake by skeletal muscle and fat and by inhibiting hepatic glucose production. Lantus consists of a substitution of glycine as asparagine at N21 combining with 2 additional arginines to the carboxy terminal of B chain. The arginine amino acids are responsible for shifting the isoelectric point to 5.4 to 6.7, making the molecule more soluble in acidic pH and less soluble in physiological pH. This shift allows a subcutaneous injection of a clear solution.

Lantus treatment demands for daily dosage as injection under the skin into the subcutaneous tissue and not intravenously or by using insulin pumps. The injection is to be taken once in day time followed by 1 injection each day at the same time. The dosage is adjusted according to individual’s physical activity, severe conditions of illness and changes in food intake. It is injected into abdominal area, thigh and deltoid. The place to inject can be replaced within the region to reduce the risk of side effects.

【レポートの目次】

1. Lantus (Insulin glargine) Clinical Insight
1.1 Clinical Introduction
1.2 Patent Analysis by Indication
1.3 Phase of Development
1.4 Brand Names by Country/Region

Lantus Biosimilars Clinical Insight by Company

2. Insulin Glargine (Insulin U300)
2.1 Clinical Insight
2.2 Development Timeline
2.3 Patent Analysis
2.4 Phase of Development

3. Insulin Glargine – HEC Pharm
3.1 Clinical Insight
3.2 Phase of Development

4. Insulin Glargine Biosimilar – Biocon/Mylan
4.1 Clinical Insight
4.2 Development Timeline
4.3 Phase of Development

5. Insulin Glargine Biosimilar – Boehringer Ingelheim/Eli Lilly
5.1 Clinical Insight
5.2 Development Timeline
5.3 Patent Analysis
5.4 Phase of Development

6. Insulin Glargine Biosimilar – Gan & Lee Pharmaceuticals
6.1 Clinical Insight
6.2 Development Timeline
6.3 Phase of Development

7. Insulin Glargine Biosimilar – GEROPHARM
7.1 Clinical Insight
7.2 Phase of Development

8. Insulin Glargine Biosimilar – Harvest Moon Pharmaceuticals
8.1 Clinical Insight
8.2 Phase of Development

9. Insulin Glargine Biosimilar – LG Life Sciences
9.1 Clinical Insight
9.2 Phase of Development

10. Insulin Glargine Biosimilar – Paras Biopharmaceuticals
10.1 Clinical Insight
10.2 Patent Analysis
10.3 Phase of Development

11. Insulin Glargine Biosimilar – Samsung Bioepis/Merck & Co.
11.1 Clinical Insight
11.2 Development Timeline
11.3 Patent Analysis
11.4 Phase of Development

12. Insulin Glargine Biosimilar – Wockhardt
12.1 Clinical Insight
12.2 Development Timeline
12.3 Phase of Development

13. Recombinant Insulin Glargine Biosimilar – Biogenomics
13.1 Clinical Insight
13.2 Phase of Development



Table 2-1: Insulin U300 Insulin Glargine by Indicaion & Phase
Table 3-1: HEC Pharm Insulin Glargine by Indication & Phase
Table 4-1: Biocon/Mylan Insulin Glargine Biosimilar by Indication & Phase
Table 5-1: Boehringer Ingelheim/Eli Lilly Insulin Glargine Biosimilar by Indication & Phase
Table 6-1: Gan & Lee Pharmaceuticals Insulin Glargine Biosimilar by Indication & Phase
Table 7-1: GEROPHARM Insulin Glargine Biosimilar by Indication & Phase
Table 8-1: Harvest Moon Pharmaceuticals Insulin Glargine Biosimilar by Indication & Phase
Table 9-1: LG Life Sciences Insulin Glargine Biosimilar by Indication & Phase
Table 10-1: Paras Biopharmaceuticals Insulin Glargine Biosimilar by Indication & Phase
Table 11-1: Samsung Bioepis/Merck & Co. Insulin Glargine Biosimilar by Indication & Phase
Table 12-1: Wockhardt Insulin Glargine Biosimilar by Indication & Phase
Table 13-1: Biogenomics Recombinant Insulin Glargine Biosimilar by Indication & Phase



【レポートのキーワード】

ランタス、インスリングラルギン、バイオシミラー、臨床試験

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ ランタス(インスリングラルギン)バイオシミラー臨床試験&機会インサイト(Lantus (Insulin Glargine) Biosimilar Clinical Trial & Opportunity Insight)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆